Summary
AbbVie Inc.'s 2015 10-K report, filed on February 18, 2016, highlights a year of significant growth and strategic expansion. The company reported a 15% increase in worldwide net revenues, reaching $22.9 billion, driven primarily by the strong performance of its flagship drug HUMIRA, robust international sales, and the acquisition of Pharmacyclics, which brought IMBRUVICA into its portfolio. AbbVie also saw growth from its HCV treatments and other key products. The company's financial health was further bolstered by an improvement in gross margin to 80% and substantial cash flow from operations, enabling significant returns to shareholders through dividends and share repurchases. Strategically, AbbVie completed the substantial $20.8 billion acquisition of Pharmacyclics, significantly strengthening its oncology presence and pipeline, particularly with IMBRUVICA. The company also continued to invest heavily in research and development, with over 50 compounds or indications in clinical development. Key regulatory submissions and approvals occurred for HUMIRA in new indications and for pipeline assets like venetoclax, underscoring a commitment to innovation and expanding therapeutic offerings. Looking ahead, AbbVie aims to continue this growth trajectory by expanding its key brands, advancing its pipeline through R&D and strategic partnerships, and enhancing shareholder value.
Financial Highlights
55 data points| Revenue | $22.86B |
| Cost of Revenue | $4.50B |
| Gross Profit | $18.36B |
| SG&A Expenses | $6.39B |
| Operating Expenses | $15.32B |
| Operating Income | $7.54B |
| Interest Expense | $719.00M |
| Net Income | $5.14B |
| EPS (Basic) | $3.15 |
| EPS (Diluted) | $3.13 |
| Shares Outstanding (Basic) | 1.63B |
| Shares Outstanding (Diluted) | 1.64B |
Key Highlights
- 1AbbVie reported a 15% increase in worldwide net revenues to $22.9 billion in 2015, primarily driven by HUMIRA and the acquisition of Pharmacyclics.
- 2The acquisition of Pharmacyclics for $20.8 billion was completed in May 2015, significantly bolstering AbbVie's oncology portfolio with IMBRUVICA.
- 3HUMIRA sales grew 12% globally (19% constant currency), accounting for approximately 61% of total net revenues in 2015, demonstrating its continued importance.
- 4Research and development expenses increased by 30% to $4.3 billion, reflecting investment in a pipeline of over 50 compounds in clinical development.
- 5The company generated strong operating cash flow of $7.5 billion, supporting significant capital allocation towards dividends ($3.3 billion) and share repurchases ($2.8 billion).
- 6AbbVie continued to expand HUMIRA's indications, receiving approvals for hidradenitis suppurativa and pediatric plaque psoriasis, and filing for uveitis.
- 7IMBRUVICA, acquired with Pharmacyclics, is expected to be a significant contributor to revenue growth, with AbbVie filing for expanded indications and receiving priority review status.